转移性肾细胞癌免疫检查点抑制剂最佳应答后延迟肾切除术的肿瘤学结局
这项全国性回顾性评估纳入30例转移性肾细胞癌患者,均在转移灶对免疫检查点抑制剂(ICI)治疗达完全缓解(CR)或主要部分缓解(>80%)后接受延迟肾切除术。中位随访19.5个月,76.7%患者达无病生存,1年时66.7%患者停用全身治疗。转移灶达CR者无病生存(p=0.022)和无进展生存(p=0.014)优于主要部分缓解者。
要点
- 转移灶对ICI达CR或主要部分缓解(>80%)后行延迟肾切除术,76.7%患者达无病生存。
- 术后1年66.7%患者停用全身治疗,1年无进展生存率96.7%、总生存率100%。
- 转移灶达CR者无病生存(p=0.022)和无进展生存(p=0.014)优于主要部分缓解者。
核心结论
- 尽管手术可能具有挑战性,对ICI治疗有应答的患者行延迟肾切除术提供了有希望的肿瘤学结局,且多数患者能够停用全身治疗。
研究设计与样本
- 全国性回顾性评估,纳入30例转移性肾细胞癌患者,均在转移灶对ICI治疗达完全缓解(CR)或主要部分缓解(>80%)后接受延迟肾切除术。
主要发现
- ICI方案包括伊匹木单抗-纳武利尤单抗(40%)、ICI+酪氨酸激酶抑制剂(10%)和纳武利尤单抗(50%)。
- 延迟肾切除术在中位ICI治疗时长10个月后进行,19例(63.3%)因粘连或炎性改变导致手术困难。
- 16.7%患者达病理完全缓解。
- 肾切除术后中位随访19.5个月,76.7%患者达无病生存,1年时66.7%患者停用全身治疗。
- 1年无进展生存率和总生存率分别为96.7%和100%,2年分别为78.3%和86.1%;转移灶达CR者无病生存(p=0.022)和无进展生存(p=0.014)优于主要部分缓解者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the current era of immune checkpoint inhibitors (ICIs), the role and optimal timing of a nephrectomy in patients with metastatic renal cell carcinoma (mRCC) remain unknown. OBJECTIVE: To assess the oncological outcomes of patients who responded to ICI-based treatments and were subsequently treated with a delayed nephrectomy. DESIGN, SETTING, AND PARTICIPANTS: This national retrospective evaluation included 30 patients with mRCC who underwent a nephrectomy after a complete response (CR) or a major partial response (>80%) to ICI treatment at metastatic sites. INTERVENTION: Partial or radical nephrectomy after a favorable response to ICI treatment. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and potential discontinuation of systemic treatment were assessed. RESULTS AND LIMITATIONS: ICI-based treatments included ipilimumab-nivolumab (40%), ICI + tyrosine kinase inhibitor (10%), and nivolumab (50%). A delayed nephrectomy was performed after a median ICI treatment duration of 10 mo. In 19 cases (63.3%), surgeons faced difficulties due to adhesions or inflammatory changes. A complete pathological response was observed in 16.7% of patients. After a median follow-up of 19.5 mo after nephrectomy, 76.7% of patients achieved DFS. At 1 yr, 66.7% of patients were free from systemic treatment. The PFS and OS rates were, respectively, 96.7% and 100% at 1 yr, and 78.3% and 86.1% at 2 yr. Patients with a CR at metastatic sites had a better prognosis than those with a major partial response, in terms of DFS (p = 0.022) and PFS (p = 0.014). CONCLUSIONS: Despite potentially challenging surgery, a delayed nephrectomy for patients who responded to ICI treatment provided promising oncological outcomes, and the majority of patients could discontinue systemic treatment. PATIENT SUMMARY: In this study, we evaluated the clinical outcome in patients who responded well to immunotherapy, and subsequently underwent kidney ablation surgery. Three-quarters of patients experienced no recurrence, and in most cases, medical treatment could be discontinued.
引用
- Pignot G, Thiery-Vuillemin A, Albigès L, et al. Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma. Eur Urol Oncol. 2022. PMID: 35853818. doi:10.1016/j.euo.2022.07.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。